IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts

Glioblastoma (GBM) is a devastating cancer with basically no curative treatment. Even with aggressive treatment, the median survival is disappointing 14 months. Surgery remains the key treatment and the postoperative survival is determined by the extent of resection. Unfortunately, the invasive grow...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurbegovic, Sorel, Juhl, Karina, Sørensen, Kasper Kildegaard, Leth, Julie, Willemoe, Gro Linno, Christensen, Anders, Adams, Yvonne, Jensen, Anja Ramstedt, von Buchwald, Christian, Skjøth-Rasmussen, Jane, Ploug, Michael, Jensen, Knud J., Kjaer, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210614/
https://www.ncbi.nlm.nih.gov/pubmed/34158842
http://dx.doi.org/10.7150/thno.49787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210614/
https://www.ncbi.nlm.nih.gov/pubmed/34158842
http://dx.doi.org/10.7150/thno.49787

Ejemplares similares